The objective response rate was 70%, with 45% of patients achieving a complete response or better. The Food and Drug Administration (FDA) has granted accelerated approval to Lynozyfic ™ (linvoseltamab ...

InoPd with inobrodib 20 mg previously demonstrated response rates at least 2x greater than alternatives for heavily pretreated pomalidomide-refractory patients following bispecific T cell engager or ...

Dr. Nooka presents a case-based approach to treatment selection using a 50-year-old woman with relapsed/refractory multiple myeloma who progressed after 15 months on lenalidomide maintenance following ...

All-oral therapies provide an attractive treatment option for patients with relapsed/refractory multiple myeloma, given their administration, the convenience of outpatient dosing, and the decreased ...

Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, and operational considerations in relapsed/refractory multiple myeloma.

Last month, C4 Therapeutics dosed the first patient in its Phase II MOMENTUM trial of cemsidomide, combined with ...

Please provide your email address to receive an email when new articles are posted on . The treatment is approved for heavily pretreated patients. Researchers reported an objective response rate of 70 ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. The good news, I guess, is that we have ...

PHILADELPHIA--(BUSINESS WIRE)-- GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this 12-part journey through a disease state ...

Discussion of patient selection criteria, logistical challenges, toxicity management, and when to favor each immunotherapy approach. The final portion of the discussion focuses on future directions in ...

C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the first patient has been ...